Skip to main content
. 2024 Oct 24;15:1473284. doi: 10.3389/fneur.2024.1473284

Figure 2.

Figure 2

NEDA-3 rates by treatment epoch. NEDA-3 was defined as no confirmed relapses, no Gd+ T1 lesions, no new or enlarging T2 lesions, and no 12-week confirmed disability progression. Pooled post hoc analysis. Modified intention-to-treat population. Gd+, gadolinium-enhancing; NEDA-3, 3-parameter no evidence of disease activity.